

Package leaflet: Information for the patient

[Invented Name] 25 mg film-coated tablets
[Invented Name] 50 mg film-coated tablets
[Invented Name] 100 mg film-coated tablets

Sitagliptin

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What [Invented Name] is and what it is used for
2. What you need to know before you take [Invented Name]
3. How to take [Invented Name]
4. Possible side effects
5. How to store [Invented Name]
6. Contents of the pack and other information

1. What [Invented Name] is and what it is used for

[Invented Name] contains the active substance sitagliptin which is a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus.

This medicine helps to increase the levels of insulin produced after a meal and decreases the amount of sugar made by the body.

Your doctor has prescribed this medicine to help lower your blood sugar, which is too high because of your type 2 diabetes. This medicine can be used alone or in combination with certain other medicines (insulin, metformin, sulphonylureas, or glitazones) that lower blood sugar, which you may already be taking for your diabetes together with a food and exercise plan.

What is type 2 diabetes?

Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation.

2. What you need to know before you take [Invented Name]

Do not take [Invented Name]

- if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or pharmacist before taking [Invented Name].

Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving [Invented Name] (see section 4).

If you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid.

Z komentarzem [MD1]: Assessor's comment

The Applicant has submitted the variation type IB (C.I.) to update of Product Information in line with the current QRD template. Moreover, some editorial changes have been introduced to the common version as well as national translations of the Product Information.

The scope of the application do not includes the use of a grey background or addition of proposed wording to the Product Information due to the removal of 25 mg and 50 mg tablets from Czech.

The Applicant is asked to remove changes that do not apply to the scope of application: DZL-ZLE.4021.2986-2988.2025.

— sformatowano: Czcionka: Nie Pogrubienie

Your doctor may ask you to stop [Invented Name].

Tell your doctor if you have or have had:

- a disease of the pancreas (such as pancreatitis)
- gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood. These medical conditions can increase your chance of getting pancreatitis (see section 4).
- type 1 diabetes
- diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss, nausea or vomiting)
- any past or present kidney problems
- an allergic reaction to [Invented Name] (see section 4).

This medicine is unlikely to cause low blood sugar because it does not work when your blood sugar is low. However, when this medicine is used in combination with a sulphonylurea medicine or with insulin, low blood sugar (hypoglycaemia) can occur. Your doctor may reduce the dose of your sulphonylurea or insulin medicine.

Children and adolescents

Children and adolescents below 18 years should not use this medicine. It is not effective in children and adolescents between the ages of 10 and 17 years. It is not known if this medicine is safe and effective when used in children younger than 10 years.

Other medicines and [Invented Name]

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heart beat and other heart problems). The level of digoxin in your blood may need to be checked if taking with [Invented Name].

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

You should not take this medicine during pregnancy.

It is not known if this medicine passes into breast milk. You should not take this medicine if you are breast-feeding or plan to breast-feed.

Driving and using machines

This medicine has no or negligible influence on the ability to drive and use machines.

However, dizziness and drowsiness have been reported, which may affect your ability to drive or use machines.

Taking this medicine in combination with medicines called sulphonylureas or with insulin can cause hypoglycaemia, which may affect your ability to drive and use machines or work without safe foothold.

[Invented Name] contains sodium

[Invented Name] contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-free”.

3. How to take [Invented Name]

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The usual recommended dose is:

- one 100 mg film-coated tablet
- once a day
- by mouth

If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg).

You can take this medicine with or without food and drink.

Your doctor may prescribe this medicine alone or with certain other medicines that lower blood sugar.


Diet and exercise can help your body use its blood sugar better. It is important to stay on the diet and exercise recommended by your doctor while taking [Invented Name].

The tablet 50 mg and tablet 100 mg of [Invented Name] can be divided into two equal doses.

If your physician has prescribed half a tablet 50 mg or half a tablet 100 mg, refer to the instructions below for dividing [Invented Name] tablets.

Instructions for dividing the tablet

1. Put the tablet on an even and hard surface (e.g. table, tabletop) with the tablet side up with the score line.
2. Break the tablet along a vertical line by pressing it against the surface with both forefingers as shown in figures 1 and 2.



Figures 1. and 2: Dividing the tablet of [Invented Name] in two equal doses.

If you take more [Invented Name] than you should

If you take more than the prescribed dosage of this medicine, contact your doctor immediately.

If you forget to take [Invented Name]

If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose of this medicine.

If you stop taking [Invented Name]

Continue to take this medicine as long as your doctor prescribes it so you can continue to help control your blood sugar. You should not stop taking this medicine without talking to your doctor first.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

STOP taking [Invented Name] and contact a doctor immediately if you notice any of the following serious side effects:

- Severe and persistent pain in the abdomen (stomach area) which might reach through to your back with or without nausea and vomiting, as these could be signs of an inflamed pancreas (pancreatitis).

If you have a serious allergic reaction (frequency not known), including rash, hives, blisters on the skin/peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing, stop taking this medicine and call your doctor right away. Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes.

Z komentářem [MD2]: Assessor's comment

The Applicant has submitted the variation type IB (C.I.) to update of Product Information in line with the current QRD template. Moreover, some editorial changes have been introduced to the common version as well as national translations of the Product Information.

The scope of the application do not includes the use of a grey background or addition of proposed wording to the Product Information due to the removal of 25 mg and 50 mg tablets from Czech.

The Applicant is asked to remove changes that do not apply to the scope of application: DZL-ZLE.4021.2986-2988.2025.

— sformatowano: Bez podkreślenia

Some patients have experienced the following side effects after adding sitagliptin to metformin:

Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting

Uncommon (may affect up to 1 in 100 people): stomach ache, diarrhoea, constipation, drowsiness

Some patients have experienced different types of stomach discomfort when starting the combination of sitagliptin and metformin together (frequency is common).

Some patients have experienced the following side effects while taking sitagliptin in combination with a sulphonylurea and metformin:

Very common (may affect more than 1 in 10 people): low blood sugar

Common: constipation

Some patients have experienced the following side effects while taking sitagliptin and pioglitazone:

Common: flatulence, swelling of the hands or legs

Some patients have experienced the following side effects while taking sitagliptin in combination with pioglitazone and metformin:

Common: swelling of the hands or legs

Some patients have experienced the following side effects while taking sitagliptin in combination with insulin (with or without metformin):

Common: flu

Uncommon: dry mouth

Some patients have experienced the following side effects while taking sitagliptin alone in clinical studies, or during post-approval use alone and/or with other diabetes medicines:

Common: low blood sugar, headache, upper respiratory infection, stuffy or runny nose and sore throat, osteoarthritis, arm or leg pain

Uncommon: dizziness, constipation, itching

Rare: reduced number of platelets

Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V*](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store [Invented Name]

This medicine does not require any special storage conditions.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and the carton after “EXP”. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What [Invented Name] contains

Sformatowano: Z prawej: 0 cm, Razem z następnym

- The active substance is sitagliptin. Each film-coated tablet contains sitagliptin hydrochloride monohydrate, equivalent to 25 mg, 50 mg or 100 mg sitagliptin.
- The other ingredients are:
In the tablet core: cellulose, microcrystalline, calcium hydrogen phosphate, sodium starch glycolate (typ.-A), silica colloidal anhydrous, sodium stearyl fumarate. The tablet film coating contains: poly(vinyl alcohol), macrogol 3350, talc, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172).

What [Invented Name] looks like and contents of the pack

[Invented Name] 25 mg: light pink, round, biconvex film-coated tablet; tablet diameter 5.9-6.3 mm.

[Invented Name] 50 mg: light orange, round, biconvex, film-coated tablet with dividing score on one side and debossement "50" on the other side; tablet diameter 7.9-8.3 mm. The tablet can be divided into equal doses.

[Invented Name] 100 mg: light brown, round, biconvex, film-coated tablet with dividing score on one side and debossement "100" on the other side; tablet diameter 9.9-10.4 mm. The tablet can be divided into equal doses.

Blisters Aluminium/PVC/PVDC in outer packaging. Packs of 14, 28, 30, 56, 84, 90, 98 film-coated tablets. Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

[To be completed nationally]

Manufacturer

[To be completed nationally]

This medicinal product is authorised in the Member States of the European Economic Area under the following names:

{Name of the Member State} {Name of the medicinal product} [Invented Name]

This leaflet was last revised in September 2025

Z komentarzem [MD3]: Assessor's comment

The Applicant has submitted the variation type IB (C.I.) to update of Product Information in line with the current QRD template. Moreover, some editorial changes have been introduced to the common version as well as national translations of the Product Information.

The scope of the application do not includes the use of a grey background or addition of proposed wording to the Product Information due to the removal of 25 mg and 50 mg tablets from Czech.

The Applicant is asked to remove changes that do not apply to the scope of application: DZL-ZLE.4021.2986-2988.2025.

Z komentarzem [MD4]: Assessor's comment

The Applicant has submitted the variation type IB (C.I.) to update of Product Information in line with the current QRD template. Moreover, some editorial changes have been introduced to the common version as well as national translations of the Product Information.

The scope of the application do not includes the use of a grey background or addition of proposed wording to the Product Information due to the removal of 25 mg and 50 mg tablets from Czech.

The Applicant is asked to remove changes that do not apply to the scope of application: DZL-ZLE.4021.2986-2988.2025.

— sformatowano: Czcionka: Nie Pogrubienie

Z komentarzem [MD5]: Assessor's comment

Please correct the wording medicine

Z komentarzem [MD6]: Assessor's comment

Please remove the wording to be in line with QRD Template

[Invented Name]

— sformatowano: Czcionka: Nie Pogrubienie